ReMDO coordinates regenerative medicine research with the ultimate goal of de-risking and accelerating the commercialization of regenerative medicine technologies in the global market, making patients’ lives better.
The research portfolio is comprised of four programs funded by public-private partnerships.
Universal Bioink Program
The Universal Bioink program is developing sets of hydrogels to be used as a tunable bioink that will not need to be designed from scratch. Instead, it will be akin to an out-of-the box bioink, compatible with different bioprinting platforms, such as extrusion and ink jet, and with different cell types, such as endothelial, cardiac, or muscle.
Standardized Cell Culture Media
The Cell Culture Media program is developing a well-defined, xeno-free basal medium that supports the growth and viability of cells derived from all of the three germ layers present in the human body, and that can be used in conjunction with three specific supplements, each of which has been optimized to support the expansion of cells. These germ layer-specific formulations will then be augmented with additional factors tailored to support the growth and function of several specific human cells. Because all formulations will be derived from the same “universal” basal medium, review by domestic and regulatory agencies will be greatly simplified and manufacturing costs will be substantially lowered.
Bioreactor
The Bioreactor program is developing automated platforms for the maturation of regenerative medicine products. The system will be scalable across the relevant range and configurable for relevant construct geometries.
Cell Isolation Program
The Cell Isolation program combines several cutting-edge cell isolation and purification strategies into an automated system for consistently generating cell populations. The program is developing a standardized and automated platform for isolating, preserving, and shipping highly defined cell populations from biologically complex human tissue specimens for manufacturing.
